This work will, in addition to describing the aromatic basis of capsaicin, elucidate its mechanism of action through a positive inhibition of the nerve conduction, which ultimately accounts for the various pharmacological effects of capsaicin on pain control, cardiovascular mechanisms, as well as its effects on genitourinary and gastrointestinal tracts.
- mechanism of action
- positive inhibition
The current study is a systemic review of the pharmacology and chemistry of capsaicin and capsaicinoids. The genus Capsicum is a member of the Solanaceae family that includes tomato, potato, tobacco, and petunia. The genus Capsicum consists of approximately 22 wild species and 5 domesticated species  including
Capsicum species have been used as medicinal plants to treat intestinal upsets and indigestion and also as stimulants, rubefacient, and tonic. They have also been used as folk remedies for dropsy, colic, diarrhea, asthma, arthritis, muscle cramps, and toothache. In addition,
This study was undertaken to investigate the anti‐inflammatory property of
2. Research methods
Following Ethics approval by the Animal Ethics Committee of the University of KwaZulu—Natal; Westville Campus, various parallel and comparative studies were carried out on crude extract ethyl acetate of
3. Data analysis
Experimental data obtained were analyzed and presented as means (+SEM). The data from “control” rats were used as baseline values while the mean reaction times to the pain stimulus or the writhing were recorded and subsequently analyzed, using a two‐way ANOVA. Interobserver differences were assessed by Wilcoxon and Kruskal‐Wallis tests. Student's
Statistical significance was by using a double‐tailed CI of 95% and a
The neural impulses, which originate from the nociceptors, relay through the primary afferent nerves (PAN), to the spinal cord, or via the cranial nerves to the brain stem, for those impulses that originate from the head and neck. The cell bodies of these ganglia are located in the dorsal root ganglia, or the respective cell bodies in the cases of cranial nerves V, VIII, IX, and X. By means of complex synapses, messages are relayed to ascending pathways.
There are several biochemical mediators (and neurotransmitters), which are involved in pain transmission and perception. Peripherally, the most important of these amines are the cyclo‐oxygenase agonists and the leukotrienes. Others are catecholamines, acetylcholine, vasoactive intestinal polypeptides (VIP), neuropeptides Y (NPY), cholecystokinin, 5‐hydroxytryptamine, neurotensin, tachykinin, and bradykinins [7, 8]. The opioid receptors act both centrally and peripherally. In addition, the central cyclo‐oxygenase action has been found with acetaminophen . Centrally acting neuromediators can be classified into “excitatory” and “inhibitory” neuromediators. Glutamate and aspartate are the examples of excitatory amino acids acting as neurotransmitters centrally, while substance P (SP), calcitonin gene‐related peptide (CGRP) , and growth factors (e.g., brain‐derived neurotrophic factors) are other examples. Inhibitory neuromediators include endogenous opioids, such as enkephalin and β‐endorphins. Others are gamma‐aminobutyric acid (GABA), glycine, and β‐adrenergic agonists . Conversely, any agent acting on these receptors and neuromediators have the ability to modulate pain. The aberration of inflammatory and neuropathic enhancement of pain perception as seen in allodynia (painful touch) and hyperalgesia are due to increased release of SP from
The memory of pain, neural plasticity, wide dynamic range activity, and the winding phenomenon are enhanced by
Injury leads to nociception, transduction, receptor modification, uncoordinated sprouting, and growth of injured axons and ectopic epileptic firing of nerves . Although the hypothalamus receives an enormous amount of stimuli, it is devoid of the ability to discriminate, since it is not somato‐topically organized. It is also not able to localize pain. However, discrimination and localization are possible by the third‐order neurons connecting to the prefrontal gyrus in the cerebral cortex. This is the basis for the use of secondary analgesia such as antidepressants and anticonvulsants.
The ascending order is not alone in pain modulation. There is enough evidence to suggest that the descending tracts have a role in the modulation of pain . In the late 1960s, it was observed that neurons in the dorsal horn of decerebrated animals are more responsive to painful stimuli when the spinal cord is blocked . Also in the late 1980s, electrical stimulation of the periaqueductal gyrus was found to produce profound relief of pain in animals . These studies provided scientific basis for stimulation‐produced analgesia. In addition, further studies showed that instillation of small doses of morphine in the regions such as periaqueductal system (PAG) produced significant analgesia.
Substance P is the active neurotransmitter that is released at the primary nerve endings of primary afferent neurons (PAN). It is usually synthesized at the
Expression of substance P was found to correlate with the severity of diarrhea in cryptosporidosis from the result in electrogenic chloride anion secretion [24,25] and found three kinds of current in response to substance P in bullfrog dorsal root ganglion neurons. They are either G‐protein coupled channel, slow activating I (SP); or directly opened channel, fast activating I (SP); or both, moderately activating I (SP). All the three were inwardly directed currents with the ionic mechanism underlying slow activating I (SP) deduced as closure of K+ channels. The fast‐activating channel is due to the opening of sodium channels. These correlate with the three subtypes of SP receptor, immunoreactive interneurons described in the rat basolateral amygdala . Furthermore, the secretion of HCO‐3 through secretin was abolished by substance P [15, 24, 27].
Other systems affected by substance P include the cardiovascular system. Low dose systemic administration of substance P caused hypertension and tachycardia, while unilateral or bilateral injections into the rat's
Capsaicin is the main pungent ingredient in “hot” chili peppers, and elicits a burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system [31, 32]. However, capsaicin‐induced ion refluxes increase cyclic GMP and not cyclic AMP , capsaicin has selective action on unmyelinated C‐fibers and thinly myelinated A primary sensory neurons .
Several sensory stimuli including noxious pressure, heat, and chemical irritation could affect capsaicin‐sensitive fibers, which are polymodal in nature. These nociceptors are the most abundant class of nociceptive fibers. On stimulation by capsaicin, nociceptive neurons release glutamate, which are a rapidly acting central neurotransmitter and an excitatory amino acid. Likewise, the transient receptor potential (TRP) family of ion channels are activated by a diverse range of stimuli, including heat, protons, lipids, phorbols, phosphorylation, changes in extracellular osmolarity and/or pressure, and depletion of intracellular Ca2+ stores. In all, VR 1 remains the only channel activated by vanilloids such as capsaicin .
In addition, they also express neuropeptides, such as calcitonin‐gene‐related‐peptide (CGRP), substance P, nerokinin A, and somatostantin, which, on release to the spinal cord, leads to intense stimulation. Noxious stimulation acting on peripheral nervous system results in a long‐term increase in spinal excitability, which results in the central mechanisms of allodynia and hyperalgesia. There is neuronal cooperation and enhancement of activities by tachykinins (e.g., substance P and neurokinin A) and excitatory amino acids (EAAs) (e.g., glutamate), which ultimately increase synaptic activation of dorsal horn neurons via EAA receptors. Following synthesis at the dorsal root ganglia, most of the neuropeptides are exported peripherally and not centrally, to facilitate neurogenic inflammation. Capsaicin pretreatment in neonatal rats has been found to abolish the development of thermal hyperalgesia produced in a model of neuropathic pain in rats [35, 36].
An initial local application of capsaicin is algesic. However, its repeated application leads to desensitization, and its high concentration eventually blocks conduction of the C‐fibers. This results in long‐lasting sensory deficits. These properties give a logical basis for the use of capsaicin in treating pains that arise from cluster headache, complex regional pain syndrome, postmastectomy pain, postherpetic neuralgia, and diabetic neuropathy [16, 37, 38].
In his review, Caterina et al.  had shown that capsaicin has an expression‐cloning strategy based on calcium influx to isolate a functional cDNA encoding of a capsaicin receptor from sensory neurons. Capsaicin receptor is a nonselective cation channel that is structurally related to members of the transient‐receptor‐potential V1 (TRPV1) family of ion channels [36, 40, 41]. The cloned‐capsaicin receptor is also activated by increases in temperature in the noxious range, which suggests that it acts as a transducer of painful thermal stimuli
In all, 28 mammalian transient receptor potential (TRP) cation channels have been identified and regrouped into six subfamilies . These include TRPC (“canonical”), TRPV (“vanilloid”), TRPM (“melastatin”), TRPP (“polycystin”), TRPML (“mucolipin”), and TRPA (“ankyrin”). The TRPV subfamily (vanilloid receptors) comprises channels critically involved in nociception and thermo sensing. Moreover, the TRPV 1 receptors have been found in the brain, spinal cord, peripheral neurons, smooth and cardiac muscles, vascular tissues, bronchial muscles, GIT mucosa, and the urinary bladder.
The mechanism of action of capsaicin is based on neuronal desensitization to noxious stimuli. Two forms of desensitization are apparent. One is a capsaicin‐induced loss of responsiveness. This is functional and it is reversible. On the other hand is a calcium‐dependent desensitization involving the activation of phosphatase and leading to the inactivation of capsaicin channel.
High doses of capsaicin may lead to neurotoxicity. Axonal and terminal degeneration and impaired nociception appear to be irreversible. Both osmotic lysis and action of calcium‐dependent proteases may be responsible for capsaicin‐induced neurotoxicity [43–47].
In acute pain, studies in animals have shown that systemic capsaicin relieves pain in increasing doses from 0.5 to 10 mg/kg, but nerve degeneration was noted in doses of 50 mg/kg and greater. The relief was for mechano‐thermal pain [48–51]. In human studies, it requires days to weeks before beneficial effects of capsaicin can be seen .
With an increase in the levels of substance P in inflammatory and neurogenic joint diseases (arthritis), topical or intra‐articular injections of capsaicin have shown significant improvements, as well as reductions in the level of inflammatory mediators [53–57]. In the same vein, Perkins and Campbell  used 6 mg/kg of intra‐articular capsaicin to reverse mechanical hyperalgesia for several hours [59, 60].
In rheumatoid arthritis, the effect of capsaicin is mixed. Whereas Deal et al.  showed significant reduction in the level of pain intensity in 31 patients with rheumatoid arthritis of the knee following treatment with zostrix (as 0.025%) for 4 weeks, McCarthy and McCarty  did not observe any improvement in 7 patients with rheumatoid hands, using 0.75% capsaicin. However, Weisman et al. [49, 61, 62] reported that application of capsaicin (0.75%) for 6 weeks produced a reduction in inflammatory mediators, including substance P, in the synovial fluid of patients with rheumatoid arthritis. In osteoarthritis, there is evidence to show increase in the level of substance P in patients, [4, 53]. Randomized, controlled trials have also shown significant improvement in pain relief following treatment with capsaicin cream [23, 34, 43, 53].
With neuropathic pain in mind, animal studies using intrathecal as well as subcutaneous or topical capsaicin have produced significant improvements in the relief of hyperalgesia and pain [37, 63–66, 72]. These studies show that capsaicin‐sensitive nerves have a role in thermal hyperalgesia in the animals under study [66, 67].
Studies in humans with neuropathic pain include patients with postherpetic neuralgia [51, 68], diabetic neuropathy , and postmastectomy pain . Others include the use of capsaicin in stump or phantom pain , complex regional pain syndrome type I , trigeminal neuralgia , and oral neuropathic pain . Capsaicin was also studied in cluster headache, and fibromyalgia , as well as in acute or chronic conditions, such as osteoarthritis [48, 64]; and rheumatoid arthritis .
Notable among these studies are those by the Capsaicin Study Group  with a total of 277 patients (138 capsaicin 0.075%, 139 placebo) having diabetic neuropathy. The Group reported significant improvements in all measures (pain, walking, working, and sleeping) after administering capsaicin four times daily for up to 8 weeks. In their study, Jensen and Larson  found that capsaicin cream provides an alternative treatment option with a favorable outcome in painful diabetic neuropathy. Most of these studies were performed over similar periods of time, except the study by Watson et al. , which followed up 83 patients with postherpetic neuralgia for 2 years. The investigators found that in 86% of their patients, improvements in the pain scores were either maintained or further enhanced with no serious side effects. Furthermore, the efficacy of nasal application of capsaicin in the treatment of cluster headache had been confirmed following 7 days application of capsaicin with significant improvement when compared with placebo. The relief might have been produced through the effects of capsaicin on substance P–containing trigeminal nerve [76, 77].
Capsaicin has also been shown to relief pruritus in patients with psoriasis [28, 70, 78], brachioradial pruritus , aquagenic pruritus , notalgia parasthetica , nodular prurigo , and pruritus produced in patients on hemodialysis . In human volunteers, capsaicin treatment was found to have inhibited itch after histamine and allergen challenge. Itch is mediated by a subset of capsaicin‐sensitive nociceptive neurons through the inhibition of C fiber conduction [82, 83].
The wide systemic side effects have made topical capsaicin to be more acceptable in clinical state. The main side effects are neuronal, cardiovascular, mucocutaneous tissue, or open wounds. Electron microscopic observations have revealed degeneration and glial engulfment of buttons and unmyelinated axons in the dorsal horn, 2–6 hours after neonatal subcutaneous capsaicin injections in rats. There is increased latency of the nerves; convulsion and even death may follow with very high doses of capsaicin [84, 85]. Cannabinoids have been used to attenuate capsaicin‐evoked hyperalgesia  and low‐dose lidocaine was found to reduce capsaicin‐evoked secondary analgesia by a central mechanism .
When capsaicin is in contact with mucocutaneous tissues, such as the conjunctiva, it produces intense inflammatory reaction . This is consequent upon the initial release of substance P. Cardiovascular studies on blood vessels have shown that both capsaicinoids and capsaicin could inhibit vasoconstriction induced by norepinephrine , and the vasodilatation effect of capsaicinoids might be due to the action of capsaicin. The compounds also cause significant decreases in platelet aggregation induced by ADP and collagen and increase blood flow in volunteers. During their study in Thailand, Jaiarj et al.  first noticed that people who consume large amounts of red chili peppers experienced a lower incidence of thromboembolism, or potentially dangerous blood clots.
The alternative to the mixed actions of capsaicin is being looked into through the development of purer and more potent capsaicin analogs. Refs. [72, 79, 80, 62] reported significant thermal and mechanical analgesia and antiinflammatory activity following administration of olvanil oleamide, an analog, which lacked the acute toxicity of capsaicin. Nuvanil was found to be more soluble, thus allowing for oral administration, and also showed improved oral activity and significant analgesia [6,87]. The compounds were also found to show less pungency and reduced vagal‐mediated blood pressure reflexes [6,79, 80, 83, 87]. In this regard, Lee et al.  and Lee and Gauci  discussed how acute toxicity of capsaicin can be prevented through structural modification. Moreover, Chen et al.  and Hua et al.  also reported that orally active capsaicin analog, civamide, showed a significant increase in response latency on the thermal withdrawal test that persisted for 3 days in adult rats.
From the synopsis above, it is obvious that capsaicin is a peripheral analgesic, which is cell specific. The opening of capsaicin‐operated channels is required for efficacy and agonism. Improvement in the therapeutic window is required before the use of an orally active therapeutic drug. However, topical applications of capsaicin have been shown to be effective without side effect [34, 37]. There is also a growing body of evidence for the role of capsaicin in inflammation, coagulation, and gastro‐intestinal function.